169 related articles for article (PubMed ID: 10357404)
21. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
Bunn PA; Kelly K
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
[TBL] [Abstract][Full Text] [Related]
22. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas.
Lokich J; Anderson N; Moore C; Bern M; Coco F; Sonneborn H; Dow E; Strong D
Eur J Cancer; 1998 Apr; 34(5):664-7. PubMed ID: 9713271
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus.
Belani CP; Luketich JD; Landreaneau RJ; Kim R; Ramanathan RK; Day R; Ferson PF; Keenan RJ; Posner M; Seeger J; Lembersky B
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-89-S19-92. PubMed ID: 9427275
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus.
Polee MB; Kok TC; Siersema PD; Tilanus HW; Splinter TA; Stoter G; Van der Gaast A
Anticancer Drugs; 2001 Jul; 12(6):513-7. PubMed ID: 11459997
[TBL] [Abstract][Full Text] [Related]
26. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.
Barone C; Corsi DC; Pozzo C; Cassano A; Fontana T; Noviello MR; Landriscina M; Colloca G; Astone A
Cancer; 1998 Apr; 82(8):1460-7. PubMed ID: 9554521
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C
Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491
[TBL] [Abstract][Full Text] [Related]
29. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction.
Schnirer II; Komaki R; Yao JC; Swisher S; Putnam J; Pisters PW; Roth JA; Ajani JA
Am J Clin Oncol; 2001 Feb; 24(1):91-5. PubMed ID: 11232959
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.
Polee MB; Eskens FA; van der Burg ME; Splinter TA; Siersema PD; Tilanus HW; Verweij J; Stoter G; van der Gaast A
Br J Cancer; 2002 Mar; 86(5):669-73. PubMed ID: 11875723
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
Bokemeyer C; Hartmann JT; Lampe CS; Clemens MR; Quietzsch D; Forkmann L; Kanz L
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-96-S19-100. PubMed ID: 9427277
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.
Kim YH; Yamaguchi K; Bang YJ; Takiuchi H; Kang WK; Sato A; Kang YK; Sakamoto J; Abe C; Sakata Y
Jpn J Clin Oncol; 2007 Jul; 37(7):501-8. PubMed ID: 17673470
[TBL] [Abstract][Full Text] [Related]
34. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
37. The activity of paclitaxel in gastrointestinal tumors.
Ajani JA; Ilson DH; Kelsen DP
Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report.
Kelsen D; Ginsberg R; Bains M; Cooper J; Arquette M; Forastiere AA; Ilson D
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-77-S19-81. PubMed ID: 9427272
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Forastiere A; Arquette M; Costa F; Heelan R; Huang Y; Kelsen DP
Cancer J; 2000; 6(5):316-23. PubMed ID: 11079171
[TBL] [Abstract][Full Text] [Related]
40. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
